TY - JOUR T1 - Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02950-2021 SP - 2102950 AU - Eva Van Braeckel AU - Iain Page AU - Jesper Rømhild Davidsen AU - Christian B. Laursen AU - Ritesh Agarwal AU - Ana Alastruey-Izquierdo AU - Aleksandra Barac AU - Jacques Cadranel AU - Arunaloke Chakrabarti AU - Oliver A. Cornely AU - David W. Denning AU - Holger Flick AU - Jean-Pierre Gangneux AU - Cendrine Godet AU - Yuta Hayashi AU - Christophe Hennequin AU - Martin Hoenigl AU - Muhammed Irfan AU - Koichi Izumikawa AU - Won-Jun Koh AU - Chris Kosmidis AU - Christoph Lange AU - Bernd Lamprecht AU - Francois Laurent AU - Oxana Munteanu AU - Rita Oladele AU - Thomas F. Patterson AU - Akira Watanabe AU - Helmut J.F. Salzer Y1 - 2022/01/01 UR - http://erj.ersjournals.com/content/early/2022/02/24/13993003.02950-2021.abstract N2 - Chronic pulmonary aspergillosis (CPA) is an uncommon but dreaded complication of many respiratory diseases occurring in non- or mildly immunocompromised patients [1]. CPA affects approximately three million people worldwide, an estimation which is undoubtedly affected by underreporting of this neglected disease [2]. The morbidity and mortality is high with 5-year survival rates of 15–60% depending on comorbidities and age [3, 4]. The diagnosis of CPA is typically established on a combination of clinical, radiological and microbiological criteria all present for at least 3 months and the absence of an alternative diagnosis [1]. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA), besides other disease entities, including chronic fibrosing pulmonary aspergillosis (CFPA), Aspergillus nodule(s) and single aspergilloma. Subacute invasive pulmonary aspergillosis (SAIA) also called chronic necrotising pulmonary aspergillosis usually occurs in moderately immunocompromised patients and comprises a more rapidly progressive clinical course (<3 months) [1].FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: R. Agarwal has received grants from Cipla Pharmaceuticals, India outside the submitted work. A. Alastruey-Izquierdo has received honoraria for lectures from Gilead and Pfizer. O.A. Cornely reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley. D.W. Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; Acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Zambon, Biosergen, TFF Pharmaceuticals, Bright Angel Therapeutics and Cipla; Sits on the DSMB for a SARS-CoV-2 vaccine trial; Honoraria for talks from Hikma, Gilead, BioRad, Basilea, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group. H. Flick participated in the past 3 years on advisory boards from Boehringer-Ingelheim and INSMED and has received honoraria for lectures and travel support from Boehringer-Ingelheim, MSD, Roche, Novartis, AstraZeneca, GSK, Chiesi, Pfizer and GSK. C. Godet has received honoraria for lectures and travel support from Pfizer and MSD; fees for board memberships from SOS Oxygène and Pulmatrix; grant support from Ohre Pharma, Boerhringer-Ingelheim, Pfizer, MSD, SOS Oxygène, ISIS Medical, Vivisol, Elivie, CF Sante, Oxyvie LVL Medicaland and AstraZeneca; grant to the University of Poitiers from the French Ministry of Health for NEBULAMB and CPAAARI clinical trial. C. Hennequin has received funds for basic research from MSD; received travel grants from Pfizer and Gilead and has received honoraria for talks by Gilead. M. Hoenigl has received research funds from NIH, Gilead, Euroimmune, Astellas, Pfizer, F2G and MSD. K. Izumikawa has received research funds and speakers honoraria from Astellas Pharma Inc., Pfizer Japan Inc., MSD K.K. a subsidiary of Merck & Co., Inc., Asahi Kasei Pharma Cooperation and Sumitomo Dainippon Pharma Co., Ltd. C. Lange has received honoraria for talks from Chiesi, Gilead, Novartis, Oxfordimmunotec, Janssen and Insmed. T.F. Patterson has received grant support to UT Health San Antonio from Cidara, F2G and Gilead and was a consultant or served on data review committees for Appili, Basilea, Mayne, Merck, Pfizer, Scynexis and Sfunga. A. Watanabe has received research funding from Shionogi & Co. Ltd. and Eiken Chemical Co. Ltd. E. van Braeckel, I. Page, J.R. Davidsen, C.B. Laursen, A. Barac, J. Cadranel, J.P. Gangneux, Y. Hayashi, M. Irfan, W.J. Koh, C. Kosmidis, B. Lamprecht, F. Laurent, O. Munteanu, R. Oladele, A. Chakrabarti and H.J.F. Salzer have no conflict of interest. ER -